Kardia 6L ECG Interpretation in Dual-Chamber LBBAP Pacing: AV Synchrony, P-Wave Morphology, and EF Trajectory After Upgrade

A consumer 6-lead ECG in a patient with a dual-chamber transvenous pacemaker and left bundle branch area pacing (LBBAP) raises specific interpretive questions: Are the P-waves intrinsic or paced? Is the AV interval optimized? Are atrial and ventricular capture present? And — most critically for clinical decision-making — does the tracing actually support a prediction of continued ejection fraction decline? This article walks through each question systematically and, where the data permit a confident answer, gives one.

Clinical context

The case under analysis: a 71-year-old male with prior dual-chamber transvenous pacemaker placement under fluoroscopic guidance with left bundle branch area pacing (LBBAP) and recruitment of LBB capture. Background includes complete heart block substrate, prior high right ventricular pacing burden under an earlier device configuration, progressive ejection fraction (EF) decline from approximately 56% to a current range of 45–55%, persistently elevated high-sensitivity troponin T (hs-TnT ~40–42 ng/L), and a recently noted capture threshold rise (2.75 V to 3.5 V) at the most recent device interrogation.

The recording analyzed is a Kardia 6L bipolar tracing acquired on April 29, 2026 at 06:14 AM, 30 seconds duration, heart rate 60 bpm, Kardia determination "Unclassified." Standard caveats apply: low gain, no chest leads, consumer-device sampling and filtering can attenuate narrow-duration pacing artifact and small atrial deflections relative to a clinical 12-lead.

1. P-wave morphology

Across the cleaner strips (pages 3–5 of the recording, free of motion artifact present on page 2), discrete low-amplitude deflections precede each QRS:

• Lead I, aVL: small upright P-wave
• Lead II: small negative or biphasic deflection preceding QRS
• Lead III, aVF: shallow negative deflections
• aVR: small positive deflection

In a patient with a dual-chamber device and an atrial lead in the right atrial appendage (RAA) — the most common atrial lead position — atrial-paced P-waves typically display this exact pattern: upright in I and aVL, negative or biphasic in inferior leads (II, III, aVF), positive in aVR. The wavefront propagates from the high-lateral right atrium downward and rightward, away from the inferior leads, producing the inferior negativity.

This morphology is therefore consistent with RAA pacing, not with sinus rhythm and not with low atrial / ectopic atrial rhythm. The narrow, monomorphic, beat-to-beat-stable shape further supports a paced rather than ectopic origin.

2. Programmed AV interval

Measuring from the onset of the atrial deflection to the onset of QRS (paper speed 25 mm/s, each small box = 40 ms):

Paced AV interval ≈ 180–200 ms (≈ 4.5–5 small boxes), constant beat-to-beat across the entire 30-second sample.

This represents the programmed AV delay of the device, not an intrinsic PR interval. For LBBAP-equipped dual-chamber pacemakers, AV delays in this range are typical: long enough to allow physiologic AV coupling and avoid pseudo-fusion, short enough to ensure consistent ventricular capture from the LBB lead and prevent breakthrough through any residual native conduction.

3. Atrial pacing spikes

Modern bipolar pacing spikes are frequently invisible or barely visible on Kardia 6L tracings because:

• Bipolar tip-to-ring spike duration is approximately 0.4–0.5 ms — at the edge of consumer-device temporal resolution
• The Kardia "Enhanced Filter" attenuates high-frequency narrow deflections
• Consumer gain settings compress small-amplitude deflections visually

Careful inspection of pages 3–5 shows suggestion of small sharp deflections immediately preceding the P-waves, particularly visible at the start of lead I complexes, but these are at the resolution limit of the device. Definitive confirmation or exclusion of atrial pacing spikes from a Kardia 6L tracing alone is generally not possible.

The clean way to answer the atrial capture question is the device interrogation itself: the percent atrial pacing (%Ap) counter on the most recent check directly answers whether the atrium is being paced.

4. Atrial capture: are the atria captured by the lead?

Synthesizing the findings, atrial capture is most likely present. Supporting features:

• P-wave axis consistent with RAA pacing (negative inferior leads, upright in I/aVL, positive in aVR)
• Constant AV interval at 180–200 ms across all beats — characteristic of a programmed delay, not native PR variability
• Regular rate at exactly 60 bpm — suggesting a programmed lower rate limit
• QRS morphology consistent with LBB-area capture (relatively narrow paced QRS, the goal of LBBAP)

Definitive confirmation requires the device counters: %Ap and %Vp on the most recent interrogation, and ideally a magnet-mode 12-lead to expose pacing artifact at maximum amplitude.

5. The harder question: does residual AV asynchrony predict continued EF decline?

The clinically meaningful question is not whether the surface ECG looks paced — it does — but whether residual electromechanical AV dyssynchrony or suboptimal LBB capture is driving ongoing myocardial dysfunction, and on what timeline EF might be expected to drop further.

What this single ECG can and cannot establish about AV synchrony

Mechanical AV synchrony depends on the electromechanical AV interval at the myocardial level, not solely on the programmed AV delay measured on surface ECG. A programmed sensed/paced AV delay of 180–200 ms with RAA pacing and LBBAP is, on paper, physiologically reasonable. The resting Kardia tracing alone does not demonstrate that meaningful AV dyssynchrony exists.

What would actually demonstrate residual dyssynchrony or suboptimal pacing physiology:

• Echo-derived AV optimization showing E/A fusion, truncated A-wave, or diastolic mitral regurgitation (AVD too long), or A-wave cut off by ventricular contraction (AVD too short)
• Pseudo-pacemaker syndrome physiology from prolonged interatrial conduction even with DDD pacing
• Intermittent loss of LBB capture, with reversion to LV septal or non-selective capture and a wider QRS
• Rate-related AVD mismatch during exertion if the rate-adaptive AVD is not optimally programmed

None of these are visible on a 30-second resting consumer 6-lead recording.

Why a "months until EF reaches 40%" prediction is not appropriate from this data

Three structural reasons preclude offering a numeric timeline:

The premise may be inverted. Prior EF decline (56% → 45–55% range) was documented under a predominantly RV pacing regime — the classic pacemaker-induced cardiomyopathy (PICM) substrate. LBBAP upgrade is the intervention designed to reverse or halt that trajectory. Published LBBAP-for-PICM cohorts (Vijayaraman, Sharma, Jastrzębski, Huang and others) consistently show EF recovery, not further decline, in the 6–12 month post-upgrade window — typical recovery of 5–10 absolute EF points in responders, with response rates of 70–80%. The base-rate expectation after a successful LBBAP upgrade is improvement or stability, not progression to 40%.

The hs-TnT signal complicates the picture. Persistently elevated hs-TnT at 40–42 ng/L suggests an ongoing myocardial injury or strain process that is not purely pacing-induced. Chronic troponin elevation of that magnitude in a structurally near-normal heart with successful LBBAP is unusual, and may indicate a parallel substrate (microvascular, infiltrative, ischemic, or strain-related from suboptimal AV programming) that AV optimization alone will not fully address.

EF trajectory is not predictable to month-level resolution in any individual. Even in pure PICM cohorts with continued RV pacing, the variance in decline rate is large — some patients lose 10 points in a year, others remain stable for a decade. Producing "X months to EF 40%" from a 30-second resting consumer ECG would be fabricated precision.

6. The actionable questions instead

Higher-yield questions for the next electrophysiology consultation:

1. Is LBB capture genuinely present and stable? A capture threshold rise from 2.75 V to 3.5 V is the most clinically concerning variable in this dataset. It can represent lead micro-dislodgement, fibrosis at the LBB capture site, or a transition from selective LBB capture to non-selective LBB capture to LV septal capture only. Loss of true LBB capture converts the upgrade benefit back toward RV-septal-pacing physiology — and that is precisely the scenario in which EF decline can resume.
2. What is the current %Vp and the QRS morphology under pacing versus native conduction? Compare paced QRS duration to baseline native QRS duration. A widening paced QRS over time is a marker of capture-type drift.
3. Has AV delay optimization been performed? Echo-guided AVD optimization, or device-based algorithms where available, can meaningfully shift mechanical synchrony.
4. When was the last echocardiogram with strain imaging? If more than 6 months post-upgrade, a fresh study with global longitudinal strain is the single highest-yield test to answer the trajectory question with measured data rather than speculation.

Summary table

Bottom line

This Kardia 6L tracing shows AV-sequential pacing with a reasonable programmed AV delay and apparent LBB-area ventricular capture. It does not demonstrate ongoing AV dyssynchrony, and therefore does not support a prediction of continued EF decline to 40% on any specific timeline.

If EF is currently 45–55% with successful LBBAP, the base-rate expectation is stability or recovery in the 6–12 month window, provided LBB capture is genuine and stable. The recent capture threshold rise from 2.75 V to 3.5 V is the variable that most warrants close attention — if that rise reflects loss of true LBB capture, the dyssynchrony question becomes clinically real, and the appropriate response is lead revision rather than waiting on the EF curve.